Oncoris BioPharma Inc.
Basic information
- Head office
- 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, 105-0001
- Chief executive
- Yasuo Urata
- Capital
- 5,108,000,000 JPY (51 100 millionJPY)
- Employees (non-consolidated)
- 35 people
- Employees (consolidated)
- Start date
- 2004-03-18
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Established Oncoris BioPharma Inc. in Minato-ku, Tokyo, with the purpose of researching and developing tumor-lysis viruses and molecular-targeted anti-tumor drugs.![]()
Incorporated Oncolys BioPharma Inc. in Minato-ku, Tokyo for the research and development of oncolytic viruses and molecular targeted anti-cancer drugs![]()
OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2005 (Heisei 17) Molecular Imaging Device Research and Development Project / Malignant Tumor Treatment Support Molecular Imaging Device R&D Project grant.![]()
Obtained a grant from NEDO (New Energy and Industrial Technology Development Organization) for research on OBP-401 (TelomeScan) entitled 'Molecule Imaging Device Research and Development Project/Malignant Tumor Treatment Support Molecule Imaging Device Research and Development Project'![]()
Submitted an IND (Investigational New Drug) application for OBP-301 to the U.S. Food and Drug Administration (FDA).![]()
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-301 (Telomelysin)![]()
Entered an exclusive worldwide licensing agreement with Yale University (USA) for a novel HIV treatment drug and began research and development as OBP-601 (Censavudine).![]()
Concluded a worldwide Exclusive License Agreement with Yale University (U.S.A.) on a new HIV drug, OBP-601(Censavudine) and started research and development on it![]()
Established the Kyoto Research Center in Kyoto City, Kyoto Prefecture, and obtained a Japanese domestic patent (No. 3867968) for OBP-301.![]()
Established Kyoto Research Center in Kyoto-city, Kyoto Japan Patent 3867968 of OBP-301 (Telomelysin) was issued.![]()
Received the 5th Japan Bio-Venture Award Minister of Education, Culture, Sports, Science and Technology Prize (sponsored by Fuji Sankei Business AI).![]()
Relocated the Kyoto Research Center to Kobe City, Hyogo Prefecture, becoming the Kobe Research Center.![]()
Signed a strategic partnership agreement with Medigen Biotechnology Corp. (Taiwan) regarding OBP-301 and submitted an IND application for OBP-601 (Censavudine) to the U.S. FDA.![]()
Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin) Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine)![]()
Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin)![]()
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine)![]()
Applied for approval from the French Agency for the Safety of Health Products (AFSSAPS) to conduct Phase 1b/2a clinical trials of OBP-601 (Censavudine).![]()
Filed an application to start Phase 1b/2a clinical trial with French National Agency for the Safety of Health Products (AFSSAPS) for OBP-601(Censavudine)![]()
Signed an exclusive worldwide licensing agreement with Astellas Pharma Inc. for a novel molecular-targeted anticancer drug and began research and development as OBP-801.![]()
Concluded a worldwide exclusive license agreement with Astellas Pharma Inc. on a novel molecular targeting anti-cancer drug, and started research and development of OBP-801![]()
OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2010 (Heisei 22) Innovation Utilization Development Grant.![]()
Signed an exclusive worldwide licensing agreement with the National Institute of Advanced Industrial Science and Technology (AIST) for the novel diagnostic test OBP-1101 and began research and development.![]()
Concluded an exclusive worldwide license agreement with National Institute of Biomedical Innovation for OBP-1101 (TelomeScan F35) and started research and development of OBP-1101 (TelomeScan F35)![]()
Received the 2011 (Heisei 23) Deals of Distinction Award in the Industry-Government-Academia Collaboration category for the licensing of OBP-601 (Censavudine) at the annual meeting of the Licensing Executives Society of the United States and Canada.![]()
Concluded a collaboration research agreement with Juntendo University regarding OBP-401 (TelomeScan)![]()
Signed a joint research agreement with the National Hospital Organization Kure Medical Center / China Cancer Center using OBP-401![]()
Concluded a collaboration research agreement with National Hospital Organization Kure Medical Center and Chugoku Cancer Center regarding OBP-401 (TelomeScan)![]()
Obtained a grant from JST (Japan Science and Technology Agency) as Feasibility Study (FS) Stage, Seeds Validation Type in Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-Step) for OBP-401 (TelomeScan)![]()
Concluded a worldwide exclusive license agreement with Geron Corporation for licensing patents concerning human telomerase specific reverse transcriptase (hTERT) promoter for diagnostic use in cancer![]()
Obtained a grant from NEDO for OBP-801 as Innovation Promotion Program of Venture Support for fiscal 2010![]()
OBP-801 was selected for the NEDO (New Energy and Industrial Technology Development Organization) Innovation Practicalization Venture Support Project.![]()
Submitted an IND (Investigational New Drug) application for OBP-801 to the U.S. Food and Drug Administration (FDA).![]()
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-801![]()
Phase 1 clinical trials of the epigenetic cancer therapeutic OBP-801 were started in the United States.![]()
Commercial sales of the cancer diagnostic test OBP-401 to Deciphera Pharmaceuticals, LLC (U.S.), a company specializing in kinase inhibitor development, commenced.![]()
It was decided that the cancer diagnostic test OBP-401 would be used to validate efficacy in Deciphera Pharmaceuticals, LLC (U.S.)'s anticancer drug development.![]()
Completed the maximum tolerated dose administration of OBP-301 Phase 1/2 clinical trials in Taiwan and South Korea.![]()
Concluded a joint research agreement with Graduate School of Medicine, Nagoya University, for Telomelysin (OBP-301) combined with checkpoint inhibitor.![]()
Concluded an investigator-initiated trial agreement with National Cancer Center Hospital East for Telomelysin (OBP-301) combined with other therapies.![]()
Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery.![]()
Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanoma.![]()
Entered into a physician-led clinical trial agreement to evaluate the efficacy of combining the tumor-lysing virus OBP-301 with other therapies in patients with progressive or metastatic solid tumors, with Dr. Toshihiko Doi's research group from the Advanced Medical Care Department of the National Cancer Center Hospital East.![]()
Completed the protocol submission for the US Phase 2 clinical trial of OBP-301 targeting malignant melanoma.![]()
Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery![]()
Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanoma![]()
Established the wholly-owned subsidiary Oncolys USA Inc. in Delaware, USA, to accelerate licensing agreements for pharmaceuticals and diagnostic reagents and research and development activities, and commenced operations in New Jersey.![]()
Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA (Pharmaceuticals and Medical Devices Agency).![]()
Entered into a capital partnership agreement with US biotech venture Precision Virologics Inc., specializing in emerging infectious disease vaccine research and development.![]()
Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA(Pharmaceuticals and Medical Devices Agency)![]()
Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.![]()
Initiated dosing for the Phase 1 trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan).![]()
Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan![]()
Entered into a joint research agreement with Juntendo University for circulating tumor cells (CTC) toward the commercialization of OBP-401/OBP-1101.![]()
Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in Japan.![]()
Initiated dosing for the Phase 1 trial primarily targeting esophageal cancer, combining OBP-301 with the anti-PD-1 antibody pembrolizumab (Japan).![]()
Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in Japan![]()
Entered into a worldwide license agreement with UK-based Stabilitech for the virus preservation stabilizer patent.![]()
OBP-301 designated as a subject item under the Ministry of Health, Labour and Welfare's 'Accelerated Review Designation' system.![]()
Entered into an exclusive license and option agreement for OBP-301 in Japan and Taiwan with Chugai Pharmaceutical Co., Ltd.![]()
Initiated dosing for the Phase 2 trial primarily focused on gastric cancer and others, combining OBP-301 with anti-PD-1 antibody pembrolizumab (United States).![]()
Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.![]()
Chugai Pharmaceutical initiated dosing for the Phase 2 clinical trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan).![]()
Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan![]()
Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine).![]()
Transposon Therapeutics, Inc. (USA) entered into a worldwide exclusive license agreement for OBP-601.![]()
Signed a patent assignment agreement with Kagoshima University and began development of a novel coronavirus treatment.![]()
Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine)![]()
Been selected "suratanodeturev" for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHO.![]()
The World Health Organization (WHO) designated the international nonproprietary name of OBP-301 as suratadenoturev.![]()
Been selected “suratanodeturev” for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHO![]()
Transposon commenced dosing in a Phase 2 clinical trial (USA) for OBP-601 targeting progressive supranuclear palsy (PSP).![]()
Transposon began dosing in a Phase 2a clinical trial (USA) for OBP-601 targeting amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).![]()
Transposon completed enrollment of patients in the Phase 2 clinical trial for OBP-601 targeting progressive supranuclear palsy (PSP).![]()
Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.![]()
Completed final enrollment in the Phase 2 clinical trial of OBP-301 combined with radiation for esophageal cancer.![]()
Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan![]()
Made an announcement of the results from an investigator-initiated phase 2 clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma at ASCO 2023.![]()
Presented results of the Phase 2 clinical trial of OBP-301 combined with pembrolizumab for gastric cancer at ASCO 2023.![]()
News
There is no news.
Public records
National Tax Agency basic information4010401053237
- Trade name
- オンコリスバイオファーマ株式会社
- Trade name (kana)
- オンコリスバイオファーマ
- Name in English
- Corporation type
- 301
- Address
- 〒105-0001 東京都港区虎ノ門4丁目1番28号
- Postal code
- 1050001
- Prefecture code
- 13
- City code
- 103
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-04-17
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1744507
METI gBizINFO4010401053237
- Corporate number
- 4010401053237
- Trade name
- オンコリスバイオファーマ株式会社
- Trade name (kana)
- オンコリスバイオファーマ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都港区虎ノ門4丁目1番28号
- Postal code
- 1050001
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 港区
- City code
- 103
- Street address
- 虎ノ門4丁目1番28号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 浦田 泰生
- Capital
- 4366132000
- Employees
- 38
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-04-17
- Key information
- 4010401053237